References
- Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–178.
- Cohen JA, Rae-Grant A;, editors. Handbook of multiple sclerosis. 2nd ed. London: Springer Healthcare; 2012.
- Rudge P. Are clinical trials of therapeutic agents for MS long enough? Lancet. 1999;353(9158):1033–1034.
- Reder AT, Oger JF, Kappos L, et al. Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Mult Scler Relat Disord. 2014;3(3):294–302.
- Leray E, Vukusic S, Debouverie M, et al. Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a large-scale french observational study. PLoS One. 2015;10(7):e0132033.
- Cutter GR, Zimmerman J, Salter AR, et al. Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord. 2015;4(5):484–490.
- Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85(3):240–247.
- Fromont A, Binquet C, Rollot F, et al. Comorbidities at multiple sclerosis diagnosis. J Neurol. 2013;260(10):2629–2637.
- Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. Clin Course Disability Brain J Neurol. 1989;112(Pt 1):133–146.
- Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78(17):1315–1322.
- Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2012;21(11):1216–1220.
- Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406–419.
- Du Pasquier RA, Pinschewer DD, Merkler D. Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs. 2014;28(6):535–558.
- Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2010;221(1–2):7–14.
- Hussain RZ, Hayardeny L, Cravens PC, et al. Immune surveillance of the central nervous system in multiple sclerosis–relevance for therapy and experimental models. J Neuroimmunol. 2014;276(1–2):9–17.
- Alberts B, Johnson A, Lewis J, et al., editors. Molecular Biology of the cell. 4th ed. New York: Garland Science; 2002.
- Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):132–141.
- World Health Organization. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD); 2003 [cited 2015 Nov 10]. Available from: http://www.who.int/classifications/atcddd/en/
- Merck Serono. Rebif®. EMA Summary of Product Characteristics; 2015 [cited 2016 Feb 5]. Available from: http://www.medicines.org.uk/emc/medicine/22392
- Novartis Pharmaceuticals. Gilenya®. EMA Summary of Product Characteristics; 2015 [cited 2016 Feb 5]. Available from: http://www.medicines.org.uk/emc/medicine/24443
- Genzyme Therapeutics. Lemtrada®. EMA Summary of Product Characteristics; 2014 [cited 2016 Feb 5]. Available from: https://www.medicines.org.uk/emc/medicine/28917
- Biogen Idec Ltd. Tecfidera®. EMA Summary of Product Characteristics; 2016 [cited 2016 Feb 5]. Available from: https://www.medicines.org.uk/emc/medicine/28593
- Novartis Pharmaceuticals. Gilenya®. FDA Prescribing Information; 2015 [cited 2016 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022527s019lbl.pdf
- Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee Meeting. Alemtuzumab (BLA 103948\5139) Background Package; 2013 [cited 2016 Feb 5]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM374186.pdf
- Sanofi Aventis US. Aubagio®. FDA Prescribing Information; 2014 [cited 2016 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202992s001lbl.pdf
- Rieckmann P, O’Connor P, Francis GS, et al. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf. 2004;27(10):745–756.
- Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
- Hartung HP, Comi G, Barkhof F, et al. Sustained benefit of continuous therapy with oral fingolimod 0.5 mg or 1.25 mg as compared to switching to fingolimod after one year of treatment with interferon beta-1a in patients with relapsing-remitting multiple sclerosis: results of the TRANSFORMS study [abstract]. Mult Scler. 2010;16:S197–S352.P812.
- Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097.
- Havrdova E, Hutchinson M, Kurukulasuriya NC, et al. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107;and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother. 2013;14(15):2145–2156.
- Genzyme Therapeutics. Lemtrada®. FDA Prescribing Information; 2014 [cited 2016 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf
- Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298–304.
- Biogen Idec Ltd. Tecfidera®. FDA Prescribing Information; 2015 [cited 2016 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204063s003s008s010lbl.pdf
- Sanofi Aventis US. Aubagio®. EMA Summary of Product Characteristics; 2015 [cited 2016 Feb 5]. Available from: https://www.medicines.org.uk/emc/medicine/28533
- Henault D, Galleguillos L, Moore C, et al. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology. 2013;81(20):1768–1772.
- Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109(5):641–649.
- Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, et al. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e76.
- Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63(10):1383–1387.
- European Medicines Agency. Gilenya®. Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. 2014. Report No.: EMEA/H/C/002202/PSUV/0027. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/002202/WC500169779.pdf
- Biogen Idec Ltd. Tysabri®. FDA Prescribing Information; 2015 [cited 2016 Feb 5]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125104s950lbl.pdf
- Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–39.
- Putzki N, Clifford DB, Bischof D, et al. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab [abstract]. Mult Scler J. 2014;20(Suppl 1):FC3.1.
- Nieuwkamp DJ, Murk JL, Van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015;372(15):1474–1476.
- Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 2015;372(15):1476–1478.
- Sweetser MT, Dawson KT, Bozic C. Manufacturer’s response to case reports of PML. N Engl J Med. 2013;368(17):1659–1661.
- Biogen Idec Ltd. Tysabri®. EMA Summary of Product Characteristics; 2016 [cited 2016 Feb 5]. Available from: https://www.medicines.org.uk/emc/medicine/18447
- Sandberg-Wollheim M, Kornmann G, Bischof D, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings. Mult Sclerosis. 2011;17(4):431–440.
- Alroughani R, Almulla A, Lamdhade S, et al. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? BMJ Case Rep. 2014;2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25320259
- Hakiki B, Portaccio E, Giannini M, et al. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Sclerosis. 2012;18(11):1636–1639.
- Sangalli F, Moiola L, Barcella V, et al. What to expect after natalizumab in every-day clinical practice [abstract]. Neurology. 2012;78(Suppl 1):P06.169.
- Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13 Pt 2):1150–1151.
- Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab. 2005;90(7):4133–4137.
- Rashtak S, Dierkhising RA, Kremers WK, et al. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015;72(1):92–98.
- Lopez MM, Valenzuela JE, Alvarez FC, et al. Long-term problems related to immunosuppression. Transpl Immunol. 2006;17(1):31–35.
- Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. Curr Opin Neurol. 2011;24(3):217–223.
- Amdipharm Mercury Company Ltd. Deltastab Injection®. EMA Summary of Product Characteristics; 2015 [cited 2015 Nov 10]. Available from: https://www.medicines.org.uk/emc/medicine/10791
- Anderson LA, Lauria C, Romano N, et al. Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3435–3443.
- Yoo HG, Yu HM, Jun JB, et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol Japan Rheum Assoc. 2013;23(4):709–715.
- Rivinius R, Helmschrott M, Ruhparwar A, et al. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Des Devel Ther. 2015;9:93–102.
- Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67(8):1167–1198.
- Morton LM, Gibson TM, Clarke CA, et al. Risk of myeloid neoplasms after solid organ transplantation. Leukemia. 2014;28(12):2317–2323.
- Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296–1305.
- Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–1124. .
- Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46(6):1607–1612.
- La Mantia L, Mascoli N, Milanese C. Azathioprine. Safety profile in multiple sclerosis patients. Neurol Sci. 2007;28(6):299–303.
- Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007;4:CD003982. .
- Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1324–1329.
- Sandoz Ltd. Azathioprine. EMA Summary of Product Characteristics; 2014 [cited 2015 Nov 23]. Available from: http://www.medicines.org.uk/emc/medicine/26876/SPC/Azathioprine+50+mg+film-coated+tablets
- Berntsson SG, Katsarogiannis E, Lourenco F, et al. Progressive multifocal leukoencephalopathy and systemic lupus erythematosus: focus on etiology. Case Rep Neurol. 2016;8(1):59–65.
- Nicholas R, Chataway J. Multiple sclerosis. BMJ Clin Evid. 2009;2009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21733201
- Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 Suppl 6):S15–8.
- Hospira UK Ltd. Mitoxantrone. EMA Summary of Product Characteristics; 2012 [cited 2015 Nov 10]. Available from: https://www.medicines.org.uk/emc/medicine/10050
- Pascual AM, Tellez N, Bosca I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Sclerosis. 2009;15(11):1303–1310.
- Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463–1470.
- Buttmann M, Seuffert L, Mader U, et al. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. Neurology. 2016;86(23):2203–2207.
- Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Sclerosis. 2002;8(2):142–154.
- Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008;65(8):1044–1051.
- Harrison DM, Gladstone DE, Hammond E, et al. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Sclerosis. 2012;18(2):202–209.
- Portaccio E, Zipoli V, Siracusa G, et al. Safety and tolerability of cyclophosphamide ‘pulses’ in multiple sclerosis: a prospective study in a clinical cohort. Mult Sclerosis. 2003;9(5):446–450.
- Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136.
- Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1–2):9–18.
- Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf. 2014;13(7):989–998.
- Faulkner M. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin Drug Saf. 2015;14(11):1737–1748. .
- Vladila AM, Mitrea DA, Nica SM, et al. Progressive multifocal leukoencephalopathy associated to multiple sclerosis therapies: review of the literature. Rom J Neurol. 2015;XIV(4):205–213.
- Novartis Pharmaceuticals. Letter to Health professionals: Fingolimod (Gilenya®): premier cas de leucoencéphalopathie multifocale progressive (LEMP) rapporté chez un patient atteint de sclérose en plaques traité par fingolimod et n’ayant pas été préalablement traité par natalizumab ou par un autre médicament immunosuppresseur; 2015 [cited 2016 Jan 20]. Available from: http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjOht3Hy7jKAhVCqQ4KHc9nBaAQFggcMAA&url=http%3A%2F%2Fansm.sante.fr%2Fcontent%2Fdownload%2F76561%2F971673%2Fversion%2F1%2Ffile%2FDHPC_Gilenya_29_04_2015.pdf&usg=AFQjCNGcTsbTj89losmbS3-mvYvB4XnWoA&bvm=bv.112064104,d.ZWU
- Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582–1591.
- Cohen J, Von Rosenstiel P, Gottschalk R, et al. Long-term safety of fingolimod: an interim analysis of the LONGTERMS cohort [abstract]. Neurology. 2015;84(Suppl 14):0006.
- Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674–680.
- Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–674.
- European Medicines Agency. TERIFLUNOMIDE. Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation; Period covered by the PSUR: 2014 Sep 13 to 2015 Mar 12; 2015. Report No.: EMEA/H/C/PSUSA/00010135/201503
- O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920–930.
- Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014;3(2):133–138.
- Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014;30(2):251–262.
- Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol. 1999;141(3):424–429.
- Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol. 2001;116(2):203–208.
- Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol. 2013;33(1):56–65.
- Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657–1658.
- Hughes S IV. PML Case With Tecfidera in MS Calls for Vigilance; 2015 [cited 2016 Jan 14]. Available from: http://www.medscape.com/viewarticle/856148
- Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4(2):93–104.
- Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332–3342.
- Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–1828.
- Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839.
- Investigators CT, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–1801.
- Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8(1):31–45.
- Food & Drug Administration. FDA Briefing Information on alemtuzumab for the Peripheral and Central Nervous System Drugs Advisory Committee; 2013 [cited 2015 Nov 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM374186.pdf
- Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573–579.
- Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Sclerosis. 2016;22(9):1215–1223.
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
- Van Pesch V, Bartholome E, Bissay V, et al. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. Acta Neurol Belg. 2014;114(3):167–178.
- O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83(1):78–86.
- Manfredonia F, Pasquali L, Dardano A, et al. Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4(2):321–336.
- Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657–665.
- Biogen Idec Ltd. AVONEX. Summary of product characteristics; 2015 [cited 2016 Feb 25]. Available from: https://www.medicines.org.uk/emc/medicine/15349
- Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007;79:537–570.
- Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Sclerosis. 2016;22(6):810–816.
- Coyle PK. Switching therapies in multiple sclerosis. CNS Drugs. 2013;27(4):239–247.
- Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40(3):307–323.
- Ziemssen T, De Stefano N, Pia Sormani M, et al. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015;4(5):460–469.
- Sormani MP, De Stefano N. Defining and scoring response to IFN-beta in multiple sclerosis. Nat Rev Neurol. 2013;9(9):504–512. .
- Rio J, Tintore M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012;19(6):899–904.
- Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(2):240–245.
- Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011;6(2):e16664.
- Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Sclerosis. 2012;18(1):64–71.
- Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2010;17(1):31–37.
- Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82(14):1204–1211.
- He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015;72(4):405–413.
- Ziemssen T, Kern R, Cornelissen C. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. BMC Neurol. 2016;16:129.
- Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain J Neurol. 2012;135(Pt 10):2973–2979.
- Grulich AE, Van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.
- Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125(8):1747–1754.